ReviewClinical reviews in allergy & immunology2017
The Clinical Relevance of Anti-DFS70 Autoantibodies.
Review in Clinical reviews in allergy & immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 110 citations in OpenAlex.
- Frequency and clinical effect of the presence of anti-DFS70 antibodies in a large cohort of patients with undifferentiated connective tissue disease.Irish journal of medical science · 2026Article
- Clinical significance of anti-dense fine speckled 70 antibodies in dense fine speckled immunofluorescence positive patients, systemic autoimmune rheumatic diseases, and controls.The Indian journal of medical research · 2026Article
- Comparative evaluation of antinuclear antibody detection by indirect immunofluorescence and line immunoassay with clinical correlation in suspected autoimmune disease patients: a retrospective cross-sectional study.Clinical rheumatology · 2026Article
- Autoantibodies and vitamin D in leprosy patients in the Brazilian Amazon.BMC infectious diseases · 2026Article
- CytoBead ANA 2 assay - a novel method for the detection of antinuclear antibodies.Scientific reports · 2025Article
- Dense fine speckled antinuclear antibody patterns: Clinical correlations and implications.Current rheumatology research · 2025Article
- Sunscreen use associated with elevated prevalence of anti-nuclear antibodies in U.S. adults.Journal of autoimmunity · 2024Article
- Review
- Clinical Significance of Antibodies to DFS70 in Immunoinflammatory Rheumatic Diseases.Doklady. Biochemistry and biophysics · 2024Article
- Assessing serum anti-nuclear antibodies HEp-2 patterns in synucleinopathies.Immunity & ageing : I & A · 2024Article
- High serum prevalence of autoreactive IgG antibodies against peripheral nerve structures in patients with neurological post-COVID-19 vaccination syndrome.Frontiers in immunology · 2024Article
- Discriminating between Homogeneous (AC-1) and Dense Fine Speckled (AC-2) Antinuclear Antibody Patterns: Re-Evaluation of Immunofluorescence Imaging.Biomedicines · 2023Article
- Tumor-Associated and Systemic Autoimmunity in Pre-Clinical Breast Cancer among Post-Menopausal Women.Biomolecules · 2023Article
- Dense fine speckled nuclear immunofluorescence: A mildly reassuring antinuclear antibody pattern meriting consideration.Immunity, inflammation and disease · 2023Article
- Postacute Sequelae of SARS-CoV-2: Musculoskeletal Conditions and Pain.Physical medicine and rehabilitation clinics of North America · 2023Review
- Article
- Over-Expression of LEDGF/p75 in HEp-2 Cells Enhances Autoimmune IgG Response in Patients with Benign Prostatic Hyperplasia-A Novel Diagnostic Approach with Therapeutic Consequence?International journal of molecular sciences · 2023Article
- Myositis Autoantibodies in Patients with Suspected Post-Treatment Lyme Disease Syndrome.Life (Basel, Switzerland) · 2023Article
- Significance of the immunofluorescence staining patterns and titres of the antinuclear antibody test in paediatric rheumatology setting.Turkish journal of medical sciences · 2023Article
- The Nuclear Dense Fine Speckled (DFS) Immunofluorescence Pattern: Not All Roads Lead to DFS70/LEDGFp75.Diagnostics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite all the progress in the establishment of specific autoantibody assays, screening for antinuclear antibodies (ANA) by indirect immunofluorescence on HEp-2 cells for quality-oriented laboratory diagnosis of ANA associated rheumatic diseases (AARD) remains indispensable but is not without limitations. Recent data on the relevance of the dense fine speckled (DFS) pattern and anti-DFS70 antibodies disclosed novel possibilities to optimize the serological stepwise diagnostics of AARD. The DFS pattern on HEp-2 cells is well differentiated from the classic "homogeneous" ANA pattern associated with dsDNA antibodies. This is the most frequent pattern in high titer ANA-positive healthy persons. The most characteristic ANA specificity associated with DFS pattern is the anti-DFS70 antibody (synonym LEDGF antibody). The prevalence of anti-DFS70 antibodies in AARD patients is significantly lower compared with the prevalence in ANA-positive healthy persons. There is a negative association between anti-DFS70 antibodies and AARD, especially if no concomitant AARD-specific autoantibodies are found. Isolated anti-DFS70 antibodies are detectable in less than 1 % of AARD but are detectable in 2-22 % of healthy persons. In the presence of an isolated anti-DFS70 antibody, the posttest probability for AARD is reduced significantly. The significance of anti-DFS70 antibodies as a criterion that helps to exclude AARD is also confirmed by follow-up studies on anti-DFS70 antibodies of positive, healthy individuals, who did not develop any AARD during a 4 year observation period. Consequently, anti-DFS70 antibodies are valuable novel biomarkers for better interpretation of positive ANA in cases of negative AARD-associated autoantibodies and should be integrated in modified test algorithms to avoid unnecessary referrals and examinations of ANA-positive persons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.